Dr. Spiess provides overview of SUO session on penile cancer
“No question, we see that there’s a lot of heterogeneity in how penile cancer is managed across the United States,” says Philippe E. Spiess, MD, MS, FACS.
In this video, Philippe E. Spiess, MD, MS, FACS, discusses the key points of the penile cancer session being presented at the 2021 Society of Urologic Oncology Annual Meeting. Spiess is a genitourinary oncologist and assistant chief of surgical services at the Moffitt Cancer Center in Tampa, Florida.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
